Publications
99
Citations
3,466
Est. group size
~15
Recurring co-author estimate
Active years
24
Publishing since 2003
Meixiao Long's work uses large-scale cancer genomics and functional data to identify drug targets and biomarkers, spanning topics such as DNA repair (PARP and PRMT inhibitors), immune gene diversity across ancestries, druggable cancer genes, and clinical trials in leukemia and lymphoma. The research combines computational analysis of tumor genomes with laboratory experiments and clinical study reporting, aiming to connect cancer biology findings to potential treatments.
Publication output has grown from a low base in 2017 to a fairly steady pace of roughly 7-11 papers per year over the last several years, with some year-to-year fluctuation but no clear slowdown.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations
Cell Reports · 2026
- Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife · 2026
- Author response: Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
2026
- Author response: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
2025
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife · 2025
- Author response: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
2025
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife · 2025
- Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl
Blood · 2025
- Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife · 2024
- Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife · 2024
- Systematic illumination of druggable genes in cancer genomes
Cell Reports · 2022
- A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Blood · 2022
- The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets
Nature Cancer · 2021
- Blood×22
- Cancer Research×6
- Journal of Clinical Oncology×5
- eLife×5
- Blood Advances×4
- Christopher C. Oakes
Medicine · The Ohio State University
- James S. Blachly
Medicine · The Ohio State University
- Daniel Jones
Medicine · The Ohio State University
- Charles T. Gregory
Medicine · The Ohio State University
- John Byrd
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile